Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Orlistat is a popular drug approved for long-term use which produces weight loss by
inhibiting triglycerides, main components of fats in the diet and reducing dietary fat
absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not
been described yet. The FA composition of RBCs, plasma and platelets can be used to monitor
of many pathological processes. This study presents alteration of FA composition in RBCM and
phospholipids, triglycerides and cholesteryl esters from plasma of health obese female
volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months.